<DOC>
	<DOCNO>NCT02555683</DOCNO>
	<brief_summary>This study aim determine efficacy safety QAW039 ( Dose 1 Dose 2 ) , compare placebo , add GINA step 4 5 standard-of- care ( SoC ) asthma therapy ( GINA 2015 ) group ( patient severe asthma high eosinophil count patient severe asthma ) .</brief_summary>
	<brief_title>Study Efficacy Safety QAW039 Patients With Severe Asthma Inadequately Controlled With Standard Care Asthma Treatment .</brief_title>
	<detailed_description>A double-blind , placebo-controlled study evaluate efficacy safety two dos ( Dose 1 Dose 2 ) QAW039 compare placebo 52-week treatment period group ( patient severe asthma high eosinophil count patient severe asthma ) . Efficacy measure rate asthma exacerbation . In addition , asthma quality life score , asthma control score lung function assess . Safety assess adverse event monitoring .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Written inform consent assent ( applicable ) . Male female patient age ≥12 year ( ≥lower age limit allow health authority and/or ethic committee/institutional review board approval ) . A diagnosis severe asthma , uncontrolled GINA 4/5 asthma medication . Evidence airway reversibility airway hyper reactivity . FEV1 ≤80 % predict normal value patient age ≥18 year ; FEV1 ≤90 % patient age 12 &lt; 18 year An ACQ score ≥1.5 . A history 2 asthma exacerbation within 12 month prior enter study . Use investigational drug within 5 halflives study entry , within 30 day , whichever longer . Subjects participate another trial QAW039 . A QTcF ( Fridericia ) ≥450 msec ( male ) ≥460 msec ( female ) . History malignancy exception local basal cell carcinoma skin . Pregnant nursing ( lactate ) woman . Serious comorbidities . Patients great 20 mg simvastatin , great 40 mg atorvastatin , great 40 mg pravastatin , great 2 mg pitavastatin</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Asthma</keyword>
	<keyword>QAW039</keyword>
</DOC>